

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported):** May 3, 2023 (~~May 3, 2023~~)

**Global Medical REIT Inc.**

(Exact name of registrant as specified in its charter)

**Maryland**  
(State or Other Jurisdiction  
of Incorporation)

**001-37815**  
(Commission  
File Number)

**46-4757266**  
(I.R.S. Employer  
Identification No.)

**7373 Wisconsin Avenue, Suite 800  
Bethesda, MD  
20814**

(Address of Principal Executive Offices)  
(Zip Code)

**(202) 524-6851**  
(Registrant's Telephone Number, Including Area Code)

**Not Applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| <b>Title of each class:</b>                           | <b>Trading Symbols:</b> | <b>Name of each exchange on which registered:</b> |
|---|-------------------------|---|
| Common Stock, par value \$0.001 per share             | GMRE                    | NYSE  |
| Series A Preferred Stock, par value \$0.001 per share | GMRE PrA                | NYSE  |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 2.02 Results of Operations and Financial Condition.**

On May 3, 2023, Global Medical REIT Inc. (the “Company”) announced its financial position as of March 31, 2023 and operating results for the three months ended March 31, 2023 and other related information (the “Earnings Release”). The Company also posted its First Quarter 2023 Earnings Supplemental (the “Supplemental”) to the Company’s website at [www.globalmedicalreit.com](http://www.globalmedicalreit.com). The Earnings Release and Supplemental are furnished as [Exhibit 99.1](#) and [Exhibit 99.2](#), respectively, and are incorporated herein by reference.

The information included in this Item 2.02 of this Current Report on Form 8-K, including the Earnings Release and Supplemental, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

| <u>Exhibit No.</u>    | <u>Description</u>  |
|-----------------------|---|
| <a href="#">99.1*</a> | <a href="#">First Quarter 2023 Earnings Release.</a>                        |
| <a href="#">99.2*</a> | <a href="#">First Quarter 2023 Earnings Supplemental.</a>                   |
| 104                   | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

\*Furnished herewith

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Global Medical REIT Inc.**

By: /s/ Jamie A. Barber  
Jamie A. Barber  
Secretary and General Counsel

Date: May 3, 2023

---



### **Global Medical REIT Announces First Quarter 2023 Financial Results**

Bethesda, MD – May 3, 2023 – (BUSINESS WIRE) – Global Medical REIT Inc. (NYSE: GMRE) (the “Company” or “GMRE”), a net-lease medical office real estate investment trust (REIT) that owns and acquires healthcare facilities and leases those facilities to physician groups and regional and national healthcare systems, today announced financial results for the three months ended March 31, 2023.

Jeffrey M. Busch, Chairman, Chief Executive Office and President stated, “Consistent with the second half of 2022, during the first quarter of 2023 we continued to navigate through the challenging acquisitions and interest rate environment by relying on the quality of our portfolio and the resilience of our tenant base. We continue to closely monitor the acquisitions market for accretive opportunities, closing one acquisition to date in 2023 for a purchase price of \$6.7 million, which was primarily financed by our issuance of OP Units priced at \$11.00 per unit. We continue to focus on renewing expiring leases and leasing our vacant space and I’m pleased with the progress we have made in those areas. With ample liquidity and continued dialogue with the seller community, we believe we are well-positioned to ramp up our acquisition activity when cap rate spreads return to an attractive level and markets normalize. I would like to thank the entire team for their collective efforts and contributions to these results.”

#### **First Quarter 2023 Highlights**

- Net income attributable to common stockholders was \$0.7 million, or \$0.01 per diluted share, as compared to \$2.7 million, or \$0.04 per diluted share, in the comparable prior year period.
- Funds from Operations (“FFO”) of \$15.1 million, or \$0.22 per share and unit, as compared to \$16.0 million, or \$0.23 per share and unit, in the comparable prior year period.
- Adjusted Funds from Operations (“AFFO”) of \$16.0 million, or \$0.23 per share and unit, as compared to \$16.8 million, or \$0.24 per share and unit, in the comparable prior year period.
- Increased total revenue 13.7% year-over-year to \$36.2 million, primarily driven by the Company’s acquisition activity since the comparable prior year period.
- Sold a medical office building located in Jacksonville, Florida, receiving gross proceeds of \$4.4 million, resulting in a gain of \$0.5 million.
- Increased portfolio leased occupancy from 96.5% at December 31, 2022 to 97.0% at March 31, 2023.

1



#### **Financial Results**

Rental revenue for the first quarter 2023 increased 13.7% year-over-year to \$36.2 million, reflecting the growth in the Company’s portfolio. First quarter 2023 rental revenue includes \$5.2 million of net lease expense recoveries, compared to \$4.0 million in the comparable prior year period.

Total expenses for the first quarter were \$34.5 million, compared to \$27.6 million for the comparable prior year period, primarily reflecting higher interest, operating, depreciation, and amortization expenses due to the growth in the Company’s portfolio since the comparable prior year period as well as the continued high interest rate environment.

Interest expense for the first quarter was \$8.3 million, compared to \$4.8 million for the comparable prior year period. This change reflects the impact of higher average borrowings and increased interest rates compared to the prior year period.

Net income attributable to common stockholders for the first quarter totaled \$0.7 million, or \$0.01 per diluted share, compared to \$2.7 million, or \$0.04 per diluted share, in the comparable prior year period.

The Company reported FFO of \$15.1 million, or \$0.22 per share and unit, and AFFO of \$16.0 million, or \$0.23 per share and unit, for the first quarter of 2023, which compares to FFO of \$16.0 million, or \$0.23 per share and unit, and AFFO of \$16.8 million, or \$0.24 per share and unit, in the comparable prior year period.

#### **Investment Activity**

During the first quarter of 2023, the Company did not complete any acquisitions and sold one medical office building located in Jacksonville, Florida receiving gross proceeds of \$4.4 million, resulting in a gain of \$0.5 million.

On April 17, 2023, the Company completed the acquisition of two medical office buildings in Redding, California for a purchase price of \$6.7 million, which was primarily financed by our issuance of OP Units at a per unit price of \$11.00.

#### **Portfolio Update**

As of March 31, 2023, the Company’s portfolio was 97.0% occupied and comprised of 4.9 million leasable square feet with an annualized base rent of \$114.9 million. As of March 31, 2023, the weighted average lease term for the Company’s portfolio was 6.0 years with weighted average annual rental escalations of 2.1%, and the Company’s portfolio rent coverage ratio was 4.1 times.

#### **Balance Sheet and Capital**

At March 31, 2023, total debt outstanding, including outstanding borrowings on the credit facility and notes payable (both net of unamortized debt issuance costs), was \$692.2 million and the Company’s leverage was 47.4%. As of March 31, 2023, the Company’s debt carried a weighted average interest rate of 4.28% and a weighted average remaining term of 3.7 years.

As of May 3, 2023, the Company’s borrowing capacity under the credit facility was \$244.5 million.



#### **Dividends**

On March 10, 2023, the Board of Directors (the "Board") declared a \$0.21 per share cash dividend to common stockholders and unitholders of record as of March 24, 2023, which was paid on April 11, 2023, representing the Company's first quarter 2023 dividend payment. The Board also declared a \$0.46875 per share cash dividend to holders of record as of April 15, 2023 of the Company's Series A Preferred Stock, which was paid on May 1, 2023. This dividend represented the Company's quarterly dividend on its Series A Preferred Stock for the period from January 31, 2023 through April 29, 2023.

#### **SUPPLEMENTAL INFORMATION**

Details regarding these results can be found in the Company's supplemental financial package available on the Investor Relations section of the Company's website at <http://investors.globalmedicalreit.com/>.

#### **CONFERENCE CALL AND WEBCAST INFORMATION**

The Company will host a live webcast and conference call on Thursday, May 4, 2023 at 9:00 a.m. Eastern Time. The webcast is located on the "Investor Relations" section of the Company's website at <http://investors.globalmedicalreit.com/>.

#### **To Participate via Telephone:**

Dial in at least five minutes prior to start time and reference Global Medical REIT Inc.  
Domestic: 1-877-704-4453  
International: 1-201-389-0920

#### **Replay:**

An audio replay of the conference call will be posted on the Company's website.

#### **NON-GAAP FINANCIAL MEASURES**

##### *General*

Management considers certain non-GAAP financial measures to be useful supplemental measures of the Company's operating performance. For the Company, non-GAAP measures consist of Earnings Before Interest, Taxes, Depreciation and Amortization for Real Estate ("EBITDAre" and "Adjusted EBITDAre"), FFO and AFFO. A non-GAAP financial measure is generally defined as one that purports to measure financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable measure determined in accordance with GAAP. The Company reports non-GAAP financial measures because these measures are observed by management to also be among the most predominant measures used by the REIT industry and by industry analysts to evaluate REITs. For these reasons, management deems it appropriate to disclose and discuss these non-GAAP financial measures.



The non-GAAP financial measures presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income, as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs. Management believes that in order to facilitate a clear understanding of the Company's historical consolidated operating results, these measures should be examined in conjunction with net income and cash flows from operations as presented elsewhere herein.

##### *FFO and AFFO*

FFO and AFFO are non-GAAP financial measures within the meaning of the rules of the United States Securities and Exchange Commission ("SEC"). The Company considers FFO and AFFO to be important supplemental measures of its operating performance and believes FFO is frequently used by securities analysts, investors, and other interested parties in the evaluation of REITs, many of which present FFO when reporting their results. In accordance with the National Association of Real Estate Investment Trusts' ("NAREIT") definition, FFO means net income or loss computed in accordance with GAAP before noncontrolling interests of holders of OP units and LTIP units, excluding gains (or losses) from sales of property and extraordinary items, less preferred stock dividends, plus real estate-related depreciation and amortization (excluding amortization of debt issuance costs and the amortization of above and below market leases), and after adjustments for unconsolidated partnerships and joint ventures. Because FFO excludes real estate-related depreciation and amortization (other than amortization of debt issuance costs and above and below market lease amortization expense), the Company believes that FFO provides a performance measure that, when compared period-over-period, reflects the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from the closest GAAP measurement, net income or loss.

AFFO is a non-GAAP measure used by many investors and analysts to measure a real estate company's operating performance by removing the effect of items that do not reflect ongoing property operations. Management calculates AFFO by modifying the NAREIT computation of FFO by adjusting it for certain cash and non-cash items and

certain recurring and non-recurring items. For the Company these items include: (a) recurring acquisition and disposition costs, (b) loss on the extinguishment of debt, (c) recurring straight line deferred rental revenue, (d) recurring stock-based compensation expense, (e) recurring amortization of above and below market leases, (f) recurring amortization of debt issuance costs, (g) recurring lease commissions, and (h) other items.

Management believes that reporting AFFO in addition to FFO is a useful supplemental measure for the investment community to use when evaluating the operating performance of the Company on a comparative basis.

#### *EBITDAre and Adjusted EBITDAre*

We calculate EBITDAre in accordance with standards established by NAREIT and define EBITDAre as net income or loss computed in accordance with GAAP plus depreciation and amortization, interest expense, gain or loss on the sale of investment properties, and impairment loss, as applicable.

We define Adjusted EBITDAre as EBITDAre plus non-cash stock compensation expense, non-cash intangible amortization related to above and below market leases, preacquisition expense and other normalizing items. Management considers EBITDAre and Adjusted EBITDAre important measures because they provide additional information to allow management, investors, and our current and potential creditors to evaluate and compare our core operating results and our ability to service debt.

---

4



#### **RENT COVERAGE RATIO**

For purposes of calculating our portfolio weighted-average EBITDARM coverage ratio ("Rent Coverage Ratio"), we excluded credit-rated tenants or their subsidiaries for which financial statements were either not available or not sufficiently detailed. These ratios are based on latest available information only. Most tenant financial statements are unaudited and we have not independently verified any tenant financial information (audited or unaudited) and, therefore, we cannot assure you that such information is accurate or complete. Certain other tenants (approximately 20% of our portfolio) are excluded from the calculation due to (i) lack of available financial information or (ii) small tenant size. Additionally, included within 20% of non-reporting tenants is Pipeline Healthcare, LLC, which filed for Chapter 11 bankruptcy protection in October of 2022. Additionally, our Rent Coverage Ratio adds back physician distributions and compensation. Management believes all adjustments are reasonable and necessary.

#### **ANNUALIZED BASE RENT**

Annualized base rent represents monthly base rent for March 2023, multiplied by 12 (or base rent net of annualized expenses for properties with gross leases). Accordingly, this methodology produces an annualized amount as of a point in time but does not take into account future (i) contractual rental rate increases, (ii) leasing activity or (iii) lease expirations. Additionally, leases that are accounted for on a cash-collected basis are not included in annualized base rent.

#### **CAPITALIZATION RATE**

The capitalization rate ("cap rate") for an acquisition is calculated by dividing current Annualized Base Rent by contractual purchase price. For the portfolio capitalization rate, certain adjustments, including for subsequent capital invested, are made to the contractual purchase price.

---

5



#### **FORWARD-LOOKING STATEMENTS**

Certain statements contained herein may be considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is the Company's intent that any such statements be protected by the safe harbor created thereby. These forward-looking statements are identified by their use of terms and phrases such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," "plan," "predict," "project," "will," "continue" and other similar terms and phrases, including references to assumptions and forecasts of future results. Except for historical information, the statements set forth herein including, but not limited to, any statements regarding our earnings, our liquidity, our tenants' ability to pay rent to us, expected financial performance (including future cash flows associated with new tenants or the expansion of current properties), future dividends or other financial items; any other statements concerning our plans, strategies, objectives and expectations for future operations and future portfolio occupancy rates, our pipeline of acquisition opportunities and expected acquisition activity, including the timing and/or successful completion of any acquisitions and expected rent receipts on these properties, our expected disposition activity, including the timing and/or successful completion of any dispositions and the expected use of proceeds therefrom, and any statements regarding future economic conditions or performance are forward-looking statements. These forward-looking statements are based on our current expectations, estimates and assumptions and are subject to certain risks and uncertainties. Although the Company believes that the expectations, estimates and assumptions reflected in its forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of the Company's forward-looking statements. Additional information concerning us and our business, including additional factors that could materially and adversely affect our financial results, include, without limitation, the risks described under Part I, Item 1A - Risk Factors, in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, and in our other filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements. The Company does not intend, and undertakes no obligation, to update any forward-looking statement.

#### **Investor Relations Contact:**

Stephen Swett  
[stephen.swett@icrinc.com](mailto:stephen.swett@icrinc.com)  
203.682.8377



**GLOBAL MEDICAL REIT INC.**  
**Condensed Consolidated Balance Sheets**  
*(unaudited, and in thousands, except par values)*

|   | As of               |                      |
|---|---------------------|----------------------|
|   | March 31,<br>2023   | December 31,<br>2022 |
| <b>Assets</b>   |                     |                      |
| Investment in real estate:  |                     |                      |
| Land  | \$ 167,285          | \$ 168,308           |
| Building  | 1,077,340           | 1,079,781            |
| Site improvements   | 22,024              | 22,024               |
| Tenant improvements   | 66,375              | 65,987               |
| Acquired lease intangible assets  | 148,249             | 148,077              |
|   | <u>1,481,273</u>    | <u>1,484,177</u>     |
| Less: accumulated depreciation and amortization   | (213,690)           | (198,218)            |
| Investment in real estate, net  | 1,267,583           | 1,285,959            |
| Cash and cash equivalents   | 4,603               | 4,016                |
| Restricted cash   | 9,378               | 10,439               |
| Tenant receivables, net   | 7,402               | 8,040                |
| Due from related parties  | 321                 | 200                  |
| Escrow deposits   | 8,625               | 7,833                |
| Deferred assets   | 30,322              | 29,616               |
| Derivative asset  | 27,428              | 34,705               |
| Goodwill  | 5,903               | 5,903                |
| Other assets  | 7,473               | 6,550                |
| Total assets  | <u>\$ 1,369,038</u> | <u>\$ 1,393,261</u>  |
| <b>Liabilities and Equity</b>   |                     |                      |
| <b>Liabilities:</b>   |                     |                      |
| Credit Facility, net of unamortized debt issuance costs of \$8,704 and \$9,253 at March 31, 2023 and December 31, 2022, respectively  | \$ 634,796          | \$ 636,447           |
| Notes payable, net of unamortized debt issuance costs of \$413 and \$452 at March 31, 2023 and December 31, 2022, respectively  | 57,367              | 57,672               |
| Accounts payable and accrued expenses   | 12,604              | 13,819               |
| Dividends payable   | 15,854              | 15,821               |
| Security deposits   | 4,688               | 5,461                |
| Other liabilities   | 8,226               | 7,363                |
| Acquired lease intangible liability, net  | 7,028               | 7,613                |
| Total liabilities   | <u>740,563</u>      | <u>744,196</u>       |
| <b>Commitments and Contingencies</b>  |                     |                      |
| <b>Equity:</b>  |                     |                      |
| Preferred stock, \$0.001 par value, 10,000 shares authorized; 3,105 issued and outstanding at March 31, 2023 and December 31, 2022, respectively (liquidation preference of \$77,625 at March 31, 2023 and December 31, 2022, respectively) | 74,959              | 74,959               |
| Common stock, \$0.001 par value, 500,000 shares authorized; 65,530 shares and 65,518 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively  | 66                  | 66                   |
| Additional paid-in capital  | 722,113             | 721,991              |
| Accumulated deficit   | (211,794)           | (198,706)            |
| Accumulated other comprehensive income  | 27,410              | 34,674               |
| Total Global Medical REIT Inc. stockholders' equity   | <u>612,754</u>      | <u>632,984</u>       |
| Noncontrolling interest   | 15,721              | 16,081               |
| Total equity  | <u>628,475</u>      | <u>649,065</u>       |
| Total liabilities and equity  | <u>\$ 1,369,038</u> | <u>\$ 1,393,261</u>  |



**GLOBAL MEDICAL REIT INC.**  
**Condensed Consolidated Statements of Operations**  
*(unaudited, and in thousands, except per share amounts)*

Three Months Ended March 31,

|  | 2023          | 2022            |
|--|---------------|-----------------|
| <b>Revenue</b>   |               |                 |
| Rental revenue   | \$ 36,199     | \$ 31,852       |
| Other income   | 31            | 23              |
| Total revenue  | 36,230        | 31,875          |
| <b>Expenses</b>  |               |                 |
| General and administrative   | 3,804         | 4,197           |
| Operating expenses   | 7,536         | 5,372           |
| Depreciation expense   | 10,494        | 9,402           |
| Amortization expense   | 4,395         | 3,777           |
| Interest expense   | 8,271         | 4,801           |
| Preacquisition expense   | 42            | 40              |
| Total expenses   | 34,542        | 27,589          |
| Income before gain on sale of investment property                            | 1,688         | 4,286           |
| Gain on sale of investment property  | 485           | —               |
| Net income   | \$ 2,173      | \$ 4,286        |
| Less: Preferred stock dividends  | (1,455)       | (1,455)         |
| Less: Net income attributable to noncontrolling interest                     | (45)          | (170)           |
| <b>Net income attributable to common stockholders</b>                        | <b>\$ 673</b> | <b>\$ 2,661</b> |
| Net income attributable to common stockholders per share – basic and diluted | \$ 0.01       | \$ 0.04         |
| Weighted average shares outstanding – basic and diluted                      | 65,525        | 65,302          |

8



**Global Medical REIT Inc.**  
**Reconciliation of Net Income to FFO and AFFO**  
*(unaudited, and in thousands, except per share and unit amounts)*

|   | Three Months Ended March 31, |                  |
|---|------------------------------|------------------|
|   | 2023                         | 2022             |
| <b>Net income</b>   | <b>\$ 2,173</b>              | <b>\$ 4,286</b>  |
| Less: Preferred stock dividends   | (1,455)                      | (1,455)          |
| Depreciation and amortization expense   | 14,861                       | 13,151           |
| Gain on sale of investment property   | (485)                        | —                |
| <b>FFO</b>  | <b>\$ 15,094</b>             | <b>\$ 15,982</b> |
| Amortization of above market leases, net  | 291                          | 199              |
| Straight line deferred rental revenue   | (763)                        | (1,195)          |
| Stock-based compensation expense  | 688                          | 1,287            |
| Amortization of debt issuance costs and other                                       | 601                          | 515              |
| Preacquisition expense  | 42                           | 40               |
| <b>AFFO</b>   | <b>\$ 15,953</b>             | <b>\$ 16,828</b> |
| <b>Net income attributable to common stockholders per share – basic and diluted</b> | <b>\$ 0.01</b>               | <b>\$ 0.04</b>   |
| <b>FFO per share and unit</b>   | <b>\$ 0.22</b>               | <b>\$ 0.23</b>   |
| <b>AFFO per share and unit</b>  | <b>\$ 0.23</b>               | <b>\$ 0.24</b>   |
| Weighted Average Shares and Units Outstanding – basic and diluted                   | 69,830                       | 69,319           |
| <b>Weighted Average Shares and Units Outstanding:</b>                               |                              |                  |
| Weighted Average Common Shares  | 65,525                       | 65,302           |
| Weighted Average OP Units   | 1,667                        | 1,672            |
| Weighted Average LTIP Units   | 2,638                        | 2,345            |
| Weighted Average Shares and Units Outstanding – basic and diluted                   | 69,830                       | 69,319           |

9



**Reconciliation of Net Income to EBITDAre and Adjusted EBITDAre**  
*(unaudited, and in thousands)*

|  | <b>Three Months Ended</b> |                  |
|--|---------------------------|------------------|
|  | <b>March 31,</b>          |                  |
|  | <b>2023</b>               | <b>2022</b>      |
| <b>Net income</b>                        | <b>\$ 2,173</b>           | <b>\$ 4,286</b>  |
| Interest expense                         | 8,271                     | 4,801            |
| Depreciation and amortization expense    | 14,889                    | 13,179           |
| Gain on sale of investment property      | (485)                     | —                |
| <b>EBITDAre</b>                          | <b>\$ 24,848</b>          | <b>\$ 22,266</b> |
| Stock-based compensation expense         | 688                       | 1,287            |
| Amortization of above market leases, net | 291                       | 199              |
| Preacquisition expense                   | 42                        | 40               |
| <b>Adjusted EBITDAre</b>                 | <b>\$ 25,869</b>          | <b>\$ 23,792</b> |



# First Quarter 2023 Earnings Supplemental

## Table of Contents


|   |       |
|---|-------|
| Company Overview                                | 3-5   |
| Select Quarterly Financial Data                 | 6     |
| Business Summary                                | 7     |
| ESG Summary                                     | 8     |
| Portfolio Summary                               | 9-10  |
| Top 10 Tenants                                  | 11-13 |
| Debt and Hedging Summary                        | 14    |
| Total Capitalization and Equity Summary         | 15    |
| Condensed Consolidated Statements of Operations | 16    |
| Condensed Consolidated Balance Sheets           | 17    |
| Condensed Consolidated Statements of Cash Flows | 18    |
| Non-GAAP Reconciliations                        | 19    |
| Reporting Definitions and Other Disclosures     | 20-21 |



## Forward-Looking Statements

Certain statements contained herein may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and it is the Company’s intent that any such statements be protected by the safe harbor created thereby. These forward-looking statements are identified by their use of terms and phrases such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “plan,” “predict,” “project,” “will,” “continue” and other similar terms and phrases, including references to assumptions and forecasts of future results. Except for historical information, the statements set forth herein including, but not limited to, any statements regarding our earnings, our liquidity, our tenants’ ability to pay rent to us, expected financial performance (including future cash flows associated with new tenants or the expansion of current properties), future dividends or other financial items; any other statements concerning our plans, strategies, objectives and expectations for future operations and future portfolio occupancy rates, our pipeline of acquisition opportunities and expected acquisition activity, including the timing and/or successful completion of any acquisitions and expected rent receipts on these properties, our expected disposition activity, including the timing and/or successful completion of any dispositions and the expected use of proceeds therefrom, and any statements regarding future economic conditions or performance are forward-looking statements. These forward-looking statements are based on our current expectations, estimates and assumptions and are subject to certain risks and uncertainties. Although the Company believes that the expectations, estimates and assumptions reflected in its forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of the Company’s forward-looking statements. Additional information concerning us and our business, including additional factors that could materially and adversely affect our financial results, include, without limitation, the risks described under Part I, Item 1A - Risk Factors, in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, and in our other filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements. The Company does not intend, and undertakes no obligation, to update any forward-looking statement.

Global Medical REIT Inc. (GMRE) is a net-lease medical office real estate investment trust (REIT) that owns and acquires healthcare facilities and leases those facilities to physician groups and regional and national healthcare systems.



### Portfolio Snapshot\*

|   |       |
|---|-------|
| Gross Investment in Real Estate (billions):     | \$1.5 |
| Number of Buildings:                            | 188   |
| Number of States:                               | 35    |
| Weighted Average Portfolio Cap Rate:            | 7.8%  |
| % of Health System or Other Affiliated Tenants: | 89%   |
| Weighted Average Lease Term (years):            | 6.0   |
| Leased Occupancy:                               | 97.0% |
| Portfolio Rent Coverage:                        | 4.1x  |

\*as of March 31, 2023



## Executive Officers

|                |   |
|----------------|---|
| Jeffrey Busch  | Chairman, Chief Executive Officer and President |
| Robert Kiernan | Chief Financial Officer and Treasurer           |
| Alfonzo Leon   | Chief Investment Officer                        |
| Danica Holley  | Chief Operating Officer                         |
| Jamie Barber   | General Counsel and Corporate Secretary         |

## Board of Directors

|                                      |   |
|--------------------------------------|---|
| Jeffrey Busch                        | Chairman, Chief Executive Officer and President   |
| Henry Cole                           | Lead Independent Director, Compensation Committee Chair, Audit Committee Member                   |
| Paula Crowley                        | Audit Committee Member, ESG Committee Member, Compensation Committee Member                       |
| Matthew Cypher, Ph.D.                | ESG Committee Chair, Nominating and Corporate Governance Committee Member                         |
| Ronald Marston                       | Nominating and Corporate Governance Committee Chair, Compensation Committee Member                |
| Dr. Roscoe Moore, Jr. <sup>(1)</sup> | Compensation Committee Member, Nominating and Corporate Governance Committee Member               |
| Lori Wittman                         | Audit Committee Chair, Nominating and Corporate Governance Committee Member, ESG Committee Member |
| Zhang Huiqi                          | Director  |

% of Independent Directors

**75%**

Board % of Women and Historically Underrepresented Minorities

**50%**

(1) On January 19, 2023, Dr. Moore notified the Company's Board of Directors that he intends to retire from the Board of Directors effective as of the Company's 2023 Annual Meeting of Stockholders to be held on May 10, 2023. Dr. Moore's decision to retire was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

## Sell-Side Analyst Coverage

| <b>Firm</b>         | <b>Name</b>       |
|---------------------|-------------------|
| Baird               | Wes Golladay      |
| BMO                 | Juan Sanabria     |
| B. Riley Securities | Bryan Maher       |
| Colliers Securities | Barry Oxford      |
| Compass Point       | Merrill Ross      |
| JMP Securities      | Aaron Hecht       |
| Janney              | Robert Stevenson  |
| KeyBanc             | Austin Wurschmidt |
| Stifel              | Stephen Manaker   |

## Investor Relations

**Stephen Swett**  
 Phone: 203.682.8377  
 Email: [stephen.swett@icrinc.com](mailto:stephen.swett@icrinc.com)

## Stock Exchange

**New York Stock Exchange**  
 Ticker: GMRE

## Corporate Headquarters

**Global Medical REIT Inc.**  
 7373 Wisconsin Avenue, Suite 800  
 Bethesda, MD 20814  
 Phone: 202.524.6851  
[www.globalmedicalreit.com](http://www.globalmedicalreit.com)

## Independent Registered Public Accounting Firm

**Deloitte & Touche LLP**  
 McLean, VA

## Corporate and REIT Tax Counsel

**Vinson & Elkins LLP**  
 Daniel LeBey, Corporate Partner  
 Christopher Mangin, REIT Tax Partner

## Transfer Agent

**American Stock Transfer & Trust Company**  
 Phone: 800.937.5449



Cobalt Rehabilitation Hospital – Surprise, AZ

# Select Quarterly Financial Data

(unaudited, and in thousands, except per share and unit amounts)

| <b>As of Period End (Unless Otherwise Specified)</b>            | <b>March 31,<br/>2023</b> | <b>December 31,<br/>2022</b> | <b>September 30,<br/>2022</b> | <b>June 30,<br/>2022</b> | <b>March 31,<br/>2022</b> |
|---|---------------------------|------------------------------|-------------------------------|--------------------------|---------------------------|
| Market capitalization (common and OP)                           | \$612,165                 | \$636,914                    | \$572,416                     | \$754,488                | \$1,094,533               |
| Market price per share – common                                 | \$9.11                    | \$9.48                       | \$8.52                        | \$11.23                  | \$16.32                   |
| Common shares and OP units outstanding                          | 67,197                    | 67,185                       | 67,185                        | 67,185                   | 67,067                    |
| Preferred equity  | \$74,959                  | \$74,959                     | \$74,959                      | \$74,959                 | \$74,959                  |
| Common equity   | \$537,795                 | \$558,025                    | \$573,707                     | \$559,053                | \$563,039                 |
| Noncontrolling interest   | \$15,721                  | \$16,081                     | \$15,918                      | \$15,097                 | \$14,619                  |
| Total equity  | \$628,475                 | \$649,065                    | \$664,584                     | \$649,109                | \$652,617                 |
| Investment in real estate, gross                                | \$1,481,273               | \$1,484,177                  | \$1,482,492                   | \$1,444,565              | \$1,368,156               |
| Borrowings:   |                           |                              |                               |                          |                           |
| Credit facility - revolver, gross                               | \$143,500                 | \$145,700                    | \$144,700                     | \$260,100                | \$186,700                 |
| Credit facility - term loan A, gross                            | \$350,000                 | \$350,000                    | \$350,000                     | \$350,000                | \$350,000                 |
| Credit facility - term loan B, gross                            | \$150,000                 | \$150,000                    | \$150,000                     | -                        | -                         |
| Notes payable, gross  | \$57,780                  | \$58,124                     | \$58,409                      | \$57,217                 | \$57,487                  |
| Weighted average interest rate for quarter                      | 4.27%                     | 4.07%                        | 3.65%                         | 2.97%                    | 2.87%                     |
| Debt covenants:   |                           |                              |                               |                          |                           |
| Leverage ratio (as defined in Credit Facility)                  | 47.4%                     | 47.6%                        | 47.6%                         | 46.2%                    | 43.7%                     |
| Fixed charge coverage ratio for quarter (1.50x minimum allowed) | 2.88                      | 3.15                         | 3.41                          | 3.59                     | 3.53                      |

| <b>Three Months Ended</b>                        | <b>March 31,<br/>2023</b> | <b>December 31,<br/>2022</b> | <b>September 30,<br/>2022</b> | <b>June 30,<br/>2022</b> | <b>March 31,<br/>2022</b> |
|--|---------------------------|------------------------------|-------------------------------|--------------------------|---------------------------|
| Rental revenue                                   | \$36,199                  | \$36,290                     | \$35,347                      | \$33,679                 | \$31,852                  |
| Interest expense                                 | \$8,271                   | \$8,064                      | \$6,963                       | \$5,401                  | \$4,801                   |
| G&A expenses                                     | \$3,804                   | \$4,051                      | \$3,961                       | \$4,336                  | \$4,197                   |
| Depreciation and amortization expenses           | \$14,889                  | \$15,093                     | \$14,415                      | \$14,036                 | \$13,179                  |
| Operating expenses                               | \$7,536                   | \$7,138                      | \$6,679                       | \$6,000                  | \$5,372                   |
| Total expenses                                   | \$34,542                  | \$34,458                     | \$32,130                      | \$29,863                 | \$27,589                  |
| Gain on sale of investment property              | \$485                     | -                            | \$6,753                       | -                        | -                         |
| Net income attributable to common stockholders   | \$673                     | \$369                        | \$8,057                       | \$2,236                  | \$2,661                   |
| Net income per share                             | \$0.01                    | \$0.01                       | \$0.12                        | \$0.03                   | \$0.04                    |
| Wtd. Avg. basic and diluted common shares (GAAP) | 65,525                    | 65,518                       | 65,518                        | 65,507                   | 65,302                    |
| FFO*   | \$15,094                  | \$15,457                     | \$16,208                      | \$16,387                 | \$15,982                  |
| FFO per share and unit*                          | \$0.22                    | \$0.22                       | \$0.23                        | \$0.24                   | \$0.23                    |
| AFFO*  | \$15,953                  | \$16,522                     | \$17,133                      | \$17,563                 | \$16,828                  |
| AFFO per share and unit*                         | \$0.23                    | \$0.24                       | \$0.25                        | \$0.25                   | \$0.24                    |
| Wtd. avg. common shares, OP and LTIP units       | 69,830                    | 69,725                       | 69,725                        | 69,698                   | 69,319                    |

## First Quarter 2023 Operating Summary

- Net income attributable to common stockholders was \$0.7 million, or \$0.01 per diluted share, as compared to \$2.7 million, or \$0.04 per diluted share, in the comparable prior year period.
- Funds from Operations (“FFO”) of \$15.1 million, or \$0.22 per share and unit, as compared to \$16.0 million, or \$0.23 per share and unit, in the comparable prior year period.
- Adjusted Funds from Operations (“AFFO”) of \$16.0 million, or \$0.23 per share and unit, as compared to \$16.8 million, or \$0.24 per share and unit, in the comparable prior year period.
- Increased total revenue 13.7% year-over-year to \$36.2 million, primarily driven by the Company’s acquisition activity since the comparable prior year period.
- Sold a medical office building in Jacksonville, Florida, receiving gross proceeds of \$4.4 million, resulting in a gain of \$0.5 million.

## Common and Preferred Dividends

- On March 10, 2023, the Board of Directors (the “Board”) declared a:
  - \$0.21 per share cash dividend to common stockholders and unitholders of record as of March 24, 2023, which was paid on April 11, 2023; and
  - \$0.46875 per share cash dividend to holders of record as of April 15, 2023, of the Company’s Series A Preferred Stock, which was paid on May 1, 2023.

## Investment Activity

- The Company did not complete any acquisitions during the first quarter of 2023.

## Capital Markets and Debt Activity

- Leverage was 47.4% as of March 31, 2023.
- As of May 3, 2023, we had unutilized borrowing capacity under the Credit Facility of \$244.5 million.
- We did not issue any shares of common stock under our ATM program during the first quarter of 2023.

## Environmental




- We continue our efforts to quantify the energy consumption of our portfolio. For the 2022 GRESB assessment report we received a score of 46 which was higher than our 2021 score.
- We utilize the ENERGY STAR platform to collect and track our energy consumption data and have identified properties that are strong candidates for the ENERGY STAR certificate program.
- We successfully completed our third project with Georgetown University Steers Center for Global Real Estate, Steers Advisory Services program. This engagement evaluated the means and methods of our utility data collection and provided actionable recommendations on improving the process for consistent quality assurance and impact. This work product will be used to establish methodology for future consumption reduction plans, and improved uniformity of data for reporting and communication purposes.
- We incorporate climate risks and environmental sustainability assessments in our due diligence process. This has yielded actionable energy consumption mitigation recommendations and immediate access to utility consumption information. Collecting this information as part of our asset evaluation supports our ESG approach of Alignment.

## Social



- Our Board continues to lead our social and governance efforts. With its diverse composition, our Board is a strong example of inclusive leadership with a composition of 38% women and 50% of individuals from underrepresented groups (including women).
- Our Board has been recognized by “Women on Boards” and our executive team reflects our demographically diverse staff.
- Our Phoenix, Arizona metro area pilot project with Ride United continued with great success. We provided 1,070 healthcare related rides to individuals in need. 60% of the rides were to medical, dental and eye appointments; 15% were to pharmacy appointments; 12% to substance use support; and 10% to mental health support. We will continue to support this program in Phoenix and expect to expand to support a similar program in Orlando, Florida.
- Our commitment to employee engagement remains a high-priority, as we continue to make accommodations for health, safety, and work-life balance. With this commitment in mind, and with the compensation committee of the Board’s leadership, we conducted an employee survey that covered a comprehensive range of subjects related to our employees’ attitudes about our work culture, compensation components, as well as demographic and identification data.

## Governance



- The Board continued to improve our corporate governance structure by adopting an incentive compensation recoupment (clawback) policy during the first quarter of 2022.
- The Board formed a standing ESG committee that oversees the Company’s environmental, social, governance and resilience efforts.
- GMRE is a member of the National Association of Corporate Directors.

(as of March 31, 2023, unless otherwise stated)

## Portfolio Statistics

|   |         |
|---|---------|
| Gross Investment in Real Estate (in billions) | \$1.5   |
| Total Buildings                               | 188     |
| Total Leasable Square Feet (in millions)      | 4.9     |
| Total Tenants                                 | 274     |
| Leased Occupancy                              | 97.0%   |
| Total Annualized Base Rent (in millions)      | \$114.9 |
| Portfolio Rent Coverage                       | 4.1x    |
| Weighted Average Cap Rate                     | 7.8%    |
| Weighted Average Lease Term (years)           | 6.0     |
| Weighted Average Rent Escalations             | 2.1%    |

## Tenant Composition

| <u>Tenant Type</u>                 | <u>% of ABR</u> |
|------------------------------------|-----------------|
| Not-for-profit healthcare system   | 35%             |
| For-profit healthcare system       | 31%             |
| Other affiliated healthcare groups | 23%             |
| <b>Total</b>                       | <b>89%</b>      |

## Lease Type

|                | <u>% of ABR</u> |
|----------------|-----------------|
| Triple-net     | 52%             |
| Absolute-net   | 40%             |
| Modified gross | 6%              |
| Gross          | 2%              |

## Rent Coverage\*



| <u>Asset Type</u>                 | <u>% of ABR</u> | <u>Ratio</u> |
|-----------------------------------|-----------------|--------------|
| MOB                               | 11%             | 5.0x         |
| MOB/ASC                           | 12%             | 3.7x         |
| Inpatient Rehab (IRF)             | 16%             | 3.8x         |
| Specialty Hospital <sup>(1)</sup> | 8%              | 3.7x         |
| <b>Total/Weighted Average</b>     | <b>47%</b>      | <b>4.1x</b>  |
| <u>Tenants Not Included</u>       |                 |              |
| Large/Credit Rated Tenants        | 33%             | N/A          |
| Not Reported                      | 20%             | N/A          |

\* See pages 20 and 21 for disclosures regarding the Company's rent coverage calculation

1) Includes surgical hospitals, long-term acute care hospitals (LTACH) and behavioral hospitals.



(as of March 31, 2023, unless otherwise stated)



### Lease Expiration Schedule (ABR in thousands)

| Year                     | # of Leases | Leasable Square Feet | % of Total Leasable Square Feet | ABR              | % of Total ABR |
|--------------------------|-------------|----------------------|---------------------------------|------------------|----------------|
| 2023                     | 66          | 355,834              | 7.3%                            | \$7,294          | 6.4%           |
| 2024                     | 65          | 704,418              | 14.4%                           | \$15,517         | 13.5%          |
| 2025                     | 43          | 370,449              | 7.6%                            | \$8,853          | 7.7%           |
| 2026                     | 60          | 524,959              | 10.7%                           | \$11,361         | 9.9%           |
| 2027                     | 43          | 477,635              | 9.8%                            | \$12,467         | 10.9%          |
| 2028                     | 19          | 170,965              | 3.5%                            | \$4,178          | 3.6%           |
| 2029                     | 23          | 471,454              | 9.6%                            | \$11,443         | 10.0%          |
| 2030                     | 27          | 395,422              | 8.1%                            | \$9,664          | 8.4%           |
| 2031                     | 13          | 287,889              | 5.9%                            | \$6,366          | 5.5%           |
| 2032                     | 7           | 80,310               | 1.6%                            | \$2,507          | 2.2%           |
| Thereafter               | 37          | 902,858              | 18.5%                           | \$25,200         | 21.9%          |
| <b>Total Leased SF</b>   | <b>403</b>  | <b>4,742,193</b>     | <b>97.0%</b>                    | <b>\$114,851</b> | <b>100.0%</b>  |
| <b>Current Vacancy</b>   |             | <b>145,543</b>       | <b>3.0%</b>                     |                  |                |
| <b>Total Leasable SF</b> |             | <b>4,887,736</b>     | <b>100.0%</b>                   |                  |                |



**1. LifePoint Health (formerly Kindred Healthcare)(B2/B).** LifePoint Health is a leading healthcare provider that serves patients, clinicians, communities and partner organizations across the healthcare continuum. Driven by a mission of *making communities healthier*, the company has a growing diversified healthcare delivery network comprised of more than 50,000 dedicated employees, 62 community hospital campuses, more than 50 rehabilitation and behavioral health hospitals and more than 200 additional sites of care, including managed acute rehabilitation units, outpatient centers and post-acute care facilities. LifePoint Health is a diversified healthcare delivery network that spans 29 states and includes 63 community hospital campuses, 32 rehabilitation and behavioral health hospitals, and more than 170 additional sites of care.

As of March 31, 2023, our LifePoint Health properties had a weighted average lease term (WALT) of 7.7 years and a total annualized base rent (ABR) of \$7.6 million. The table below summarizes our LifePoint Health properties as of March 31, 2023:

| Asset Type          | Location          | Purchase Date | Leasable Square Feet | Tenant's % Occupancy |
|---------------------|-------------------|---------------|----------------------|----------------------|
| IRF                 | Austin, TX        | Sep-2017      | 59,258               | 100%                 |
| IRF                 | Oklahoma City, OK | Apr-2019      | 63,896               | 100%                 |
| Behavioral Hospital | Fort Worth, TX    | Mar-2021      | 33,997               | 100%                 |

**2. Encompass Health (Ba3/BB-) (NYSE: EHC).** Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States. With a national footprint that includes 153 hospitals in 36 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery.

As of March 31, 2023, our Encompass properties had a WALT of 5.0 years and a total ABR of \$7.3 million. The table below summarizes our Encompass properties as of March 31, 2023:

| Asset Type | Location          | Purchase Date | Leasable Square Feet | Tenant's % Occupancy |
|------------|-------------------|---------------|----------------------|----------------------|
| IRF        | Altoona, PA       | Dec-2016      | 70,007               | 100%                 |
| IRF        | Mechanicsburg, PA | Dec-2016      | 78,836               | 100%                 |
| IRF        | Mesa, AZ          | Dec-2016      | 51,903               | 100%                 |
| IRF        | Las Vegas, NV     | Apr-2019      | 53,260               | 100%                 |

**3. Memorial Health System, OH (B+) (MHS).** MHS is the largest health system in the Parkersburg-Marietta-Vienna MSA and delivers healthcare services in southeast Ohio. MHS operates the 199-bed Marietta Memorial Hospital and two critical access hospitals, nine outpatient care centers, 26 medical staff offices, and clinical care delivery locations.

As of March 31, 2023, our MHS properties had a WALT of 7.9 years and a total ABR of \$5.5 million. The table below summarizes our MHS properties as of March 31, 2023:

| Asset Type  | Location   | Purchase Date | Leasable Square Feet | Tenant's % Occupancy |
|-------------|------------|---------------|----------------------|----------------------|
| MOB/Imaging | Belpre, OH | Apr-2018      | 50,300               | 100%                 |
| MOB         | Belpre, OH | Apr-2018      | 25,000               | 100%                 |
| MOB         | Belpre, OH | Apr-2018      | 25,000               | 100%                 |
| MOB/ASC     | Belpre, OH | Apr-2018      | 55,300               | 100%                 |

**4. Oklahoma Center for Orthopedic & Multi-Specialty Surgery, LLC (OCOM).** OCOM is an affiliate of USPI and INTEGRIS and is a leading hospital for orthopedic specialists. OCOM operates (i) a surgical hospital with six operating rooms, nine inpatient treatment rooms and a physical therapy department, (ii) an ambulatory surgery center with three operating rooms, and (iii) multiple imaging centers throughout Oklahoma City, Oklahoma.

As of March 31, 2023, our OCOM properties had a WALT of 10.6 years and a total ABR of \$3.8 million. The table below summarizes our OCOM properties as of March 31, 2023:

| Asset Type        | Location          | Purchase Date | Leasable Square Feet | Tenant's % Occupancy |
|-------------------|-------------------|---------------|----------------------|----------------------|
| Surgical Hospital | Oklahoma City, OK | Mar-2017      | 66,310               | 100%                 |
| MOB               | Oklahoma City, OK | Mar-2017      | 20,200               | 100%                 |
| ASC               | Oklahoma City, OK | Mar-2017      | 10,896               | 100%                 |

**5. Trinity Health (Aa3/AA-).** Trinity Health is one of the largest not-for-profit, Catholic health care systems in the nation. It is a family of 123,000 colleagues and nearly 27,000 physicians and clinicians caring for diverse communities across 26 states. Nationally recognized for care and experience, the Trinity Health system includes 88 hospitals, 135 continuing care locations, the second largest PACE program in the country, 136 urgent care locations and many other health and well-being services. Based in Livonia, Michigan, its annual operating revenue is \$21.5 billion with \$1.4 billion returned to its communities in the form of charity care and other community benefit programs.

As of March 31, 2023, our Trinity Health properties had a WALT of 3.6 years and a total ABR of \$3.6 million. The table below summarizes our Trinity Health properties as of March 31, 2023:

| Asset Type | Location      | Purchase Date | Leasable Square Feet | Tenant's % Occupancy |
|------------|---------------|---------------|----------------------|----------------------|
| IRF        | Mishawaka, IN | Apr-2019      | 45,920               | 100%                 |
| MOB        | Livonia, MI   | Aug-2019      | 18,825               | 29%                  |
| MOB/ASC    | Clinton, IA   | Feb-2020      | 115,142              | 100%                 |
| MOB        | Caledonia, MI | Jun-2021      | 8,936                | 63%                  |
| MOB        | Athens, GA    | Dec-2021      | 7,460                | 100%                 |

**6. TeamHealth Holdings (Caa1/CCC+).** TeamHealth, owned by Blackstone Group, is a provider of physician staffing and administrative services to hospitals and other healthcare providers in the United States. TeamHealth is affiliated with more than 15,000 healthcare professionals who provide emergency medicine, hospital medicine, anesthesia, urgent care, pediatric staffing, and management services. TeamHealth, through an affiliated entity, services U.S. military treatment facilities, VA clinics and other Federal agencies.

As of March 31, 2023, our TeamHealth properties had a WALT of 1.4 years and a total ABR of \$3.2 million. Setting aside tenant termination options, the WALT would be 6.4 years. The table below summarizes our TeamHealth properties as of March 31, 2023:

| Asset Type | Location     | Purchase Date | Leasable Square Feet | Tenant's % Occupancy |
|------------|--------------|---------------|----------------------|----------------------|
| MOB        | Dumfries, VA | Apr-2020      | 99,718               | 100%                 |
| MOB        | Fairfax, VA  | Jul-2020      | 73,653               | 100%                 |

**7. Steward Health Care.** Steward is among the nation's largest and most successful accountable care organizations (ACO), with more than 5,500 providers and 43,000 health care professionals who care for 12.3 million patients a year through a closely integrated network of hospitals, multispecialty medical groups, urgent care centers, skilled nursing facilities and behavioral health centers. Based in Dallas, Steward currently operates 39 hospitals across Arizona, Arkansas, Florida, Louisiana, Massachusetts, Ohio, Pennsylvania, Texas and Utah.

As of March 31, 2023, our Steward properties had a WALT of 2.6 years and a total ABR of \$3.1 million. The table below summarizes our Steward properties as of March 31, 2023:

| Asset Type        | Location      | Purchase Date | Leasable Square Feet | Tenant's % Occupancy |
|-------------------|---------------|---------------|----------------------|----------------------|
| Surgical Hospital | Beaumont, TX  | Oct-2019      | 84,674               | 100%                 |
| MOB               | Hialeah, FL   | Sep-2021      | 3,838                | 5%                   |
| MOB               | Hermitage, PA | Sep-2022      | 23,050               | 100%                 |

**8. Carrus Health.** Carrus Health is specialty hospital system headquartered in Sherman, Texas and delivers healthcare services in the greater Texoma area. Carrus Health provides inpatient and outpatient physical rehabilitative care, long term acute care and children's behavioral health care.

As of March 31, 2023, our Carrus Health property had a lease term of 14.3 years and a total ABR of \$2.9 million. The table below summarizes our Carrus Health property as of March 31, 2023:

| Asset Type | Location    | Purchase Date | Leasable Square Feet | Tenant's % Occupancy |
|------------|-------------|---------------|----------------------|----------------------|
| IRF        | Sherman, TX | Jun-2017      | 69,352               | 100%                 |

**9. Atrium Health (Aa3/AA-).** Based in Charlotte, North Carolina, Atrium Health is an integrated, nonprofit health system with more than 70,000 teammates serving patients at 40 hospitals and more than 1,400 care locations. Atrium Health is part of Advocate Health, the fifth-largest nonprofit health system in the United States, which was created from the combination with Advocate Aurora Health. It provides care under the Atrium Health Wake Forest Baptist name in the Winston-Salem, North Carolina, region, as well as Atrium Health Navicent and Atrium Health Floyd in Georgia and Alabama. Atrium Health is renowned for its top-ranked pediatric, cancer and heart care, as well as organ transplants, burn treatments and specialized musculoskeletal programs.

As of March 31, 2023, our Atrium Health properties had a WALT of 0.6 years and a total ABR of \$2.6 million. The table below summarizes our Atrium Health properties as of March 31, 2023:

| Asset Type | Location          | Purchase Date | Leasable Square Feet | Tenant's % Occupancy |
|------------|-------------------|---------------|----------------------|----------------------|
| MOB        | High Point, NC    | Feb-2020      | 97,811               | 100%                 |
| MOB        | Winston-Salem, NC | Sep-2020      | 45,525               | 100%                 |

**10. Pipeline Health.** Pipeline Health is a privately held, community-based hospital management company based in Los Angeles, California. In October 2022, Pipeline filed for Chapter 11 bankruptcy protection under the United States Bankruptcy Code in response to its operations at its two hospitals in Chicago, Illinois and general post-COVID-19 struggles for the hospital industry. In January 2023, Pipeline emerged from bankruptcy after successfully selling its two hospitals in Chicago, Illinois and reorganizing its business with a new management team that will focus on its operations in Texas (where it operates one hospital) and California (where it operates four hospitals). As part of the bankruptcy process, Pipeline assumed our lease at the White Rock Medical Center in Dallas, Texas with some modifications to assist Pipeline's exit from bankruptcy and its new business plan.

As of March 31, 2023, our Pipeline property had a lease term of 14.9 years and a total ABR of \$2.5 million. The table below summarizes our Pipeline property as of March 31, 2023:

| Asset Type          | Location   | Purchase Date | Leasable Square Feet | Tenant's % Occupancy |
|---------------------|------------|---------------|----------------------|----------------------|
| Acute-Care Hospital | Dallas, TX | Mar-2018      | 236,314              | 100%                 |


# Debt and Hedging Summary

(unaudited, and in thousands, except per share data)

## Debt Statistics As of March 31, 2023

|  |           |
|--|-----------|
| Total Gross Debt:                            | \$701,280 |
| Fixed Rate Debt-to-Total Debt:               | 80%       |
| Weighted Average Interest Rate (Q1):         | 4.27%     |
| End of Period Weighted Average Interest Rate | 4.28%     |
| Weighted Average Maturity (Years):           | 3.7       |
| Leverage Ratio                               | 47.4%     |
| Fixed Charge Coverage Ratio                  | 2.88      |

## Fixed-to-Floating Rate Debt



| Debt                              | Balance          | Debt Detail |                             |                         |
|-----------------------------------|------------------|-------------|-----------------------------|-------------------------|
|                                   |                  | Rate Type   | Interest Rate               | Maturity                |
| <b>Unsecured Credit Facility:</b> |                  |             |                             |                         |
| Revolver:                         | \$143,500        | Floating    | SOFR + 1.50% <sup>(1)</sup> | 8/1/2026 <sup>(1)</sup> |
| Term Loan A:                      | \$350,000        | Fixed       | 3.39% <sup>(2)</sup>        | May-26                  |
| Term Loan B:                      | \$150,000        | Fixed       | 4.15% <sup>(2)</sup>        | February-28             |
| <b>Other:</b>                     |                  |             |                             |                         |
| Cantor CMBS Loan:                 | \$31,247         | Fixed       | 5.22%                       | April-26                |
| Rosedale Loan:                    | \$13,856         | Fixed       | 3.85%                       | July-25                 |
| Dumfries CMBS Loan:               | \$11,260         | Fixed       | 4.68%                       | June-24                 |
| Toledo Loan:                      | \$1,417          | Fixed       | 5.00%                       | July-33                 |
| <b>Total/Weighted Average:</b>    | <b>\$701,280</b> |             | <b>4.28%</b>                | <b>3.7 years</b>        |

(1) Credit spread of 1.50% is based on the Company's overall leverage ratio (as defined in the credit facility agreement) being between 45% and 50% as of March 31, 2023. Pursuant to the credit facility agreement, at each reporting date the credit spread will increase or decrease based on the Company's overall leverage ratio. In addition to the credit spread we also pay 10 bps related to the transition from LIBOR to SOFR. The Revolver has two Company-controlled, six-month extension options. If the Company exercises those options, the maturity date of the Revolver would be August 2027.

(2) Rates reflect the effect of the Company's interest rate swaps. See table below for a detailed descriptions of the Company's interest rate swaps. Consists of the fixed base rate plus a credit spread of 1.45% based on a leverage ratio of between 45% and 50% under our credit facility agreement, plus 10 bps related to the transition from LIBOR to SOFR and is calculated using 365/360 method.

| Notional                | Term             | Interest Rate Swap Detail <sup>(1)</sup> |                            |
|-------------------------|------------------|--|----------------------------|
|                         |                  | Weighted Average Interest Rates          |                            |
| Term Loan A - \$350,000 | Current – 8/2023 | Fixed base rate:                         | 1.80%                      |
|                         |                  | <b>Effective interest rate:</b>          | <b>3.39%<sup>(2)</sup></b> |
|                         | 8/2023 – 8/2024  | Fixed base rate:                         | 1.50%                      |
|                         |                  | <b>Effective interest rate:</b>          | <b>3.10%<sup>(2)</sup></b> |
|                         | 8/2024 – 4/2026  | Fixed base rate:                         | 1.36%                      |
|                         |                  | <b>Effective interest rate:</b>          | <b>2.95%<sup>(2)</sup></b> |
| Term Loan B - \$150,000 | Current – 2/2028 | Fixed base rate:                         | 2.54%                      |
|                         |                  | <b>Effective interest rate:</b>          | <b>4.15%<sup>(2)</sup></b> |

(1) Consists of a total of ten current interest rates swaps and five forward starting interest rate swaps whereby we pay (or will pay) the fixed base rate listed in the table above and receive the one-month Standard Overnight Financing Rate (SOFR), which is the reference rate for the outstanding loans in our credit facility.

(2) Consists of the fixed base rate plus a credit spread of 1.45% based on a leverage ratio of between 45% and 50% under our credit facility agreement, plus 10 bps related to the transition from LIBOR to SOFR and is calculated using 365/360 method.

# Total Capitalization and Equity Summary

(unaudited, and in thousands, except per share data)

| Total Capitalization                                 | As of March 31, 2023 |
|--|----------------------|
| <b>Total Debt</b>                                    | \$701,280            |
| <b>Preferred Stock</b>                               | \$74,959             |
| <b>Common Stock<sup>(1)</sup></b>                    | \$596,978            |
| <b>OP Units (1,667 units)<sup>(1)</sup></b>          | \$15,187             |
| <b>Vested LTIP Units (2,154 units)<sup>(2)</sup></b> | \$—                  |
| <b>Total Capitalization</b>                          | <b>\$1,388,404</b>   |

(1) Based on the closing price of the Company's common stock on March 31, 2023, of \$9.11 per share.

(2) LTIPs are issued as equity compensation to the Company's directors and employees and, as such, have no capital value associated to them.



| Stock  | Equity Detail |                      |                        | Optional Redemption Period |
|--|---------------|----------------------|------------------------|----------------------------|
|  | Shares        | Dividend Rate/Yield  | Liquidation Preference |                            |
| Series A Cumulative Preferred Stock, \$0.001 par value per share | 3,105         | 7.50%                | \$25 per share         | Began on 9/15/2022         |
| Common Stock, \$0.001 par value per share                        | 65,530        | 9.22% <sup>(1)</sup> | N/A                    | N/A                        |

(1) Calculated by dividing the aggregate dividends received for the trailing four quarters by the Company's closing stock price on March 31, 2023 of \$9.11 per share.

| Preferred Dividends |              |                      |
|---------------------|--------------|----------------------|
| Record Date         | Payment Date | Dividend (per share) |
| 7/15/2022           | 8/1/2022     | \$0.46875            |
| 10/15/2022          | 10/31/2022   | \$0.46875            |
| 1/15/2023           | 1/31/2023    | \$0.46875            |
| 4/15/2023           | 5/1/2023     | \$0.46875            |
| <b>Total:</b>       |              | <b>\$1.87500</b>     |

| Common Dividends |              |                      |
|------------------|--------------|----------------------|
| Record Date      | Payment Date | Dividend (per share) |
| 6/24/2022        | 7/8/2022     | \$0.21               |
| 9/23/2022        | 10/11/2022   | \$0.21               |
| 12/22/2022       | 1/9/2023     | \$0.21               |
| 3/24/2023        | 4/11/2023    | \$0.21               |
| <b>Total:</b>    |              | <b>\$0.84</b>        |

# Condensed Consolidated Statements of Operations

(unaudited, and in thousands, except per share amounts)

|   | Three Months Ended |               |
|---|--------------------|---------------|
|   | March 31,          |               |
|   | 2023               | 2022          |
| <b>Revenue</b>  |                    |               |
| Rental revenue  | \$36,199           | \$31,852      |
| Other income  | 31                 | 23            |
| <b>Total revenue</b>  | <b>36,230</b>      | <b>31,875</b> |
| <b>Expenses</b>   |                    |               |
| General and administrative  | 3,804              | 4,197         |
| Operating expenses  | 7,536              | 5,372         |
| Depreciation expense  | 10,494             | 9,402         |
| Amortization expense  | 4,395              | 3,777         |
| Interest expense  | 8,271              | 4,801         |
| Preacquisition expense  | 42                 | 40            |
| <b>Total expenses</b>   | <b>34,542</b>      | <b>27,589</b> |
| Income before gain on sale of investment property                           | 1,688              | 4,286         |
| Gain on sale of investment property   | 485                | -             |
| Net income  | \$2,173            | 4,286         |
| Less: Preferred stock dividends   | (1,455)            | (1,455)       |
| Less: Net income attributable to noncontrolling interest                    | (45)               | (170)         |
| <b>Net income attributable to common stockholders</b>                       | <b>\$673</b>       | <b>2,661</b>  |
| Net income attributable to common stockholders per share -basic and diluted | \$0.01             | \$0.04        |
| Weighted average shares outstanding – basic and diluted                     | 65,525             | 65,302        |

# Condensed Consolidated Balance Sheets

(unaudited, and in thousands)

|  | As of              |                    |
|--|--------------------|--------------------|
|  | March 31, 2023     | December 31, 2022  |
| <b>Assets</b>  |                    |                    |
| Investment in real estate:                                 |                    |                    |
| Land   | \$167,285          | \$168,308          |
| Building   | 1,077,340          | 1,079,781          |
| Site improvements  | 22,024             | 22,024             |
| Tenant improvements  | 66,375             | 65,987             |
| Acquired lease intangible assets                           | 148,249            | 148,077            |
|  | <u>1,481,273</u>   | <u>1,484,177</u>   |
| Less: accumulated depreciation and amortization            | (213,690)          | (198,218)          |
| Investment in real estate, net                             | 1,267,583          | 1,285,959          |
| Cash and cash equivalents                                  | 4,603              | 4,016              |
| Restricted cash  | 9,378              | 10,439             |
| Tenant receivables, net                                    | 7,402              | 8,040              |
| Due from related parties                                   | 321                | 200                |
| Escrow deposits  | 8,625              | 7,833              |
| Deferred assets  | 30,322             | 29,616             |
| Derivative asset   | 27,428             | 34,705             |
| Goodwill   | 5,903              | 5,903              |
| Other assets   | 7,473              | 6,550              |
| <b>Total assets</b>  | <u>\$1,369,038</u> | <u>\$1,393,261</u> |
| <b>Liabilities and Equity</b>                              |                    |                    |
| Liabilities:   |                    |                    |
| Credit Facility, net                                       | \$634,796          | \$636,447          |
| Notes payable, net   | 57,367             | 57,672             |
| Accounts payable and accrued expenses                      | 12,604             | 13,819             |
| Dividends payable  | 15,854             | 15,821             |
| Security deposits  | 4,688              | 5,461              |
| Other liabilities  | 8,226              | 7,363              |
| Acquired lease intangible liability, net                   | 7,028              | 7,613              |
| <b>Total liabilities</b>                                   | <u>740,563</u>     | <u>744,196</u>     |
| Equity:  |                    |                    |
| Preferred stock (\$77,625 liquidation preference)          | 74,959             | 74,959             |
| Common stock   | 66                 | 66                 |
| Additional paid-in capital                                 | 722,113            | 721,991            |
| Accumulated deficit  | (211,794)          | (198,706)          |
| Accumulated other comprehensive income                     | 27,410             | 34,674             |
| <b>Total Global Medical REIT Inc. stockholders' equity</b> | <u>612,754</u>     | <u>632,984</u>     |
| Noncontrolling interest                                    | 15,721             | 16,081             |
| <b>Total equity</b>  | <u>628,475</u>     | <u>649,065</u>     |
| <b>Total liabilities and equity</b>                        | <u>\$1,369,038</u> | <u>\$1,393,261</u> |

# Condensed Consolidated Statements of Cash Flows

(unaudited, and in thousands)

|   | Three Months Ended |                 |
|---|--------------------|-----------------|
|   | March 31,          |                 |
|   | 2023               | 2022            |
| <b>Operating activities</b>   |                    |                 |
| Net income  | \$2,173            | \$4,286         |
| Adjustments to reconcile net income to net cash provided by operating activities:     |                    |                 |
| Depreciation expense  | 10,494             | 9,402           |
| Amortization of acquired lease intangible assets                                      | 4,373              | 3,755           |
| Amortization of above market leases, net  | 291                | 199             |
| Amortization of debt issuance costs and other   | 601                | 515             |
| Stock-based compensation expense  | 688                | 1,287           |
| Capitalized preacquisition and other costs charged to expense                         | 15                 | 153             |
| Gain on sale of investment property   | (485)              | —               |
| Other   | —                  | 29              |
| Changes in operating assets and liabilities:  |                    |                 |
| Tenant receivables  | 638                | (407)           |
| Deferred assets   | (811)              | (1,297)         |
| Other assets and liabilities  | (210)              | (532)           |
| Accounts payable and accrued expenses   | (1,223)            | (1,030)         |
| Security deposits   | (773)              | 76              |
| Net cash provided by operating activities   | <u>15,771</u>      | <u>16,436</u>   |
| <b>Investing activities</b>   |                    |                 |
| Purchase of land, buildings, and other tangible and intangible assets and liabilities | —                  | (24,468)        |
| Net proceeds from sale of investment property   | 4,175              | —               |
| Escrow deposits for purchase of properties  | (153)              | (1,284)         |
| Advances made to related parties  | (121)              | (288)           |
| Capital expenditures on existing real estate investments                              | (809)              | (556)           |
| Net cash provided by (used in) investing activities                                   | <u>3,092</u>       | <u>(26,596)</u> |
| <b>Financing activities</b>   |                    |                 |
| Net proceeds received from common equity offerings                                    | —                  | 8,210           |
| Escrow deposits required by third party lenders                                       | (639)              | (456)           |
| Repayment of notes payable  | (344)              | (282)           |
| Proceeds from Credit Facility   | 12,600             | 14,100          |
| Repayment of Credit Facility  | (14,800)           | —               |
| Dividends paid to common stockholders, and OP Unit and LTIP Unit holders              | (14,699)           | (14,526)        |
| Dividends paid to preferred stockholders  | (1,455)            | (1,455)         |
| Net cash (used in) provided by financing activities                                   | <u>(19,337)</u>    | <u>5,591</u>    |
| Net decrease in cash and cash equivalents and restricted cash                         | (474)              | (4,569)         |
| Cash and cash equivalents and restricted cash—beginning of period                     | <u>14,455</u>      | <u>12,759</u>   |
| Cash and cash equivalents and restricted cash—end of period                           | <u>13,981</u>      | <u>8,190</u>    |

## Non-GAAP Reconciliations

(unaudited, and in thousands, except per share and unit amounts)

|   | Three Months Ended |                      |                       |                  |                   |
|---|--------------------|----------------------|-----------------------|------------------|-------------------|
|   | March 31,<br>2023  | December 31,<br>2022 | September 30,<br>2022 | June 30,<br>2022 | March 31,<br>2022 |
| <b>FFO and AFFO</b>   |                    |                      |                       |                  |                   |
| <b>Net income</b>   | <b>\$2,173</b>     | <b>\$1,848</b>       | <b>\$10,029</b>       | <b>\$3,834</b>   | <b>\$4,286</b>    |
| Less: Preferred stock dividends   | (1,455)            | (1,455)              | (1,455)               | (1,455)          | (1,455)           |
| Depreciation and amortization expense   | 14,861             | 15,064               | 14,387                | 14,008           | 13,151            |
| Gain on sale of investment property   | (485)              | -                    | (6,753)               | -                | -                 |
| <b>FFO</b>  | <b>\$15,094</b>    | <b>\$15,457</b>      | <b>\$16,208</b>       | <b>\$16,387</b>  | <b>\$15,982</b>   |
| Amortization of above market leases, net  | 291                | 292                  | 221                   | 315              | 199               |
| Straight line deferred rental revenue   | (763)              | (1,006)              | (1,018)               | (1,032)          | (1,195)           |
| Stock-based compensation expense  | 688                | 1,066                | 1,039                 | 1,289            | 1,287             |
| Amortization of debt issuance costs and other                                       | 601                | 601                  | 571                   | 514              | 515               |
| Preacquisition expense  | 42                 | 112                  | 112                   | 90               | 40                |
| <b>AFFO</b>   | <b>\$15,953</b>    | <b>\$16,522</b>      | <b>\$17,133</b>       | <b>\$17,563</b>  | <b>\$16,828</b>   |
| <b>Net income attributable to common stockholders per share – basic and diluted</b> | <b>\$0.01</b>      | <b>\$0.01</b>        | <b>\$0.12</b>         | <b>\$0.03</b>    | <b>\$0.04</b>     |
| <b>FFO per share and unit</b>   | <b>\$0.22</b>      | <b>\$0.22</b>        | <b>\$0.23</b>         | <b>\$0.24</b>    | <b>\$0.23</b>     |
| <b>AFFO per share and unit</b>  | <b>\$0.23</b>      | <b>\$0.24</b>        | <b>\$0.25</b>         | <b>\$0.25</b>    | <b>\$0.24</b>     |
| Wtd Average Common Shares, OP and LTIP Units outstanding:                           |                    |                      |                       |                  |                   |
| Common shares   | 65,525             | 65,518               | 65,518                | 65,507           | 65,302            |
| OP units  | 1,667              | 1,668                | 1,668                 | 1,668            | 1,672             |
| LTIP units  | 2,638              | 2,539                | 2,539                 | 2,523            | 2,345             |
| Wtd Average Common Shares, OP and LTIP Units Outstanding - basic and diluted        | 69,830             | 69,725               | 69,725                | 69,698           | 69,319            |

|  | Three Months Ended |                      |                       |                  |                   |
|--|--------------------|----------------------|-----------------------|------------------|-------------------|
|  | March 31,<br>2023  | December 31,<br>2022 | September 30,<br>2022 | June 30,<br>2022 | March 31,<br>2022 |
| <b>EBITDAre and Adjusted EBITDAre</b>    |                    |                      |                       |                  |                   |
| <b>Net income</b>                        | <b>\$2,173</b>     | <b>\$1,848</b>       | <b>\$10,029</b>       | <b>\$3,834</b>   | <b>\$4,286</b>    |
| Interest expense                         | 8,271              | 8,064                | 6,963                 | 5,401            | 4,801             |
| Depreciation and amortization expense    | 14,889             | 15,093               | 14,415                | 14,036           | 13,179            |
| Gain on sale of investment property      | (485)              | -                    | (6,753)               | -                | -                 |
| <b>EBITDAre</b>                          | <b>\$24,848</b>    | <b>\$25,005</b>      | <b>\$24,654</b>       | <b>\$23,271</b>  | <b>\$22,266</b>   |
| Stock-based compensation expense         | 688                | 1,066                | 1,039                 | 1,289            | 1,287             |
| Amortization of above market leases, net | 291                | 292                  | 221                   | 315              | 199               |
| Preacquisition expense                   | 42                 | 112                  | 112                   | 90               | 40                |
| <b>Adjusted EBITDAre</b>                 | <b>\$25,869</b>    | <b>\$26,475</b>      | <b>\$26,026</b>       | <b>\$24,965</b>  | <b>\$23,792</b>   |

## **Reporting Definitions**

### **Annualized Base Rent**

Annualized base rent represents monthly base rent for March 2023, multiplied by 12 (or base rent net of annualized expenses for properties with gross leases). Accordingly, this methodology produces an annualized amount as of a point in time but does not take into account future (i) contractual rental rate increases, (ii) leasing activity or (iii) lease expirations. Additionally, leases that are accounted for on a cash-collected basis are not included in annualized base rent.

### **Capitalization Rate**

The capitalization rate ("Cap Rate") for an acquisition is calculated by dividing current Annualized Base Rent by contractual purchase price. For the portfolio capitalization rate, certain adjustments, including for subsequent capital invested, are made to the contractual purchase price.

### **Earnings Before Interest, Taxes, Depreciation and Amortization for Real Estate ("EBITDAre" and "Adjusted EBITDAre")**

We calculate EBITDAre in accordance with standards established by NAREIT and define EBITDAre as net income or loss computed in accordance with GAAP plus depreciation and amortization, interest expense, gain or loss on the sale of investment properties, and impairment loss, as applicable.

We define Adjusted EBITDAre as EBITDAre plus non-cash stock compensation expense, non-cash intangible amortization related to above and below market leases, preacquisition expense and other normalizing items. Management considers EBITDAre and Adjusted EBITDAre important measures because they provide additional information to allow management, investors, and our current and potential creditors to evaluate and compare our core operating results and our ability to service debt.

### **Funds from Operations and Adjusted Funds from Operations**

Funds from operations ("FFO") and adjusted funds from operations ("AFFO") are non-GAAP financial measures within the meaning of the rules of the SEC. The Company considers FFO and AFFO to be important supplemental measures of its operating performance and believes FFO is frequently used by securities analysts, investors, and other interested parties in the evaluation of REITs, many of which present FFO when reporting their results.

In accordance with the National Association of Real Estate Investment Trusts' ("NAREIT") definition, FFO means net income or loss computed in accordance with GAAP before noncontrolling interests of holders of OP units and LTIP units, excluding gains (or losses) from sales of property and extraordinary items, less preferred stock dividends, plus real estate-related depreciation and amortization (excluding amortization of debt issuance costs and the amortization of above and below market leases), and after adjustments for unconsolidated partnerships and joint ventures. Because FFO excludes real estate-related depreciation and amortization (other than amortization of debt issuance costs and above and below market lease amortization expense), the Company believes that FFO provides a performance measure that, when compared period-over-period, reflects the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from the closest GAAP measurement, net income or loss.

AFFO is a non-GAAP measure used by many investors and analysts to measure a real estate company's operating performance by removing the effect of items that do not reflect ongoing property operations. Management calculates AFFO by modifying the NAREIT computation of FFO by adjusting it for certain cash and non-cash items and certain recurring and non-recurring items. For the Company these items include recurring acquisition and disposition costs, loss on the extinguishment of debt, recurring straight line deferred rental revenue, recurring stock-based compensation expense, recurring amortization of above and below market leases, recurring amortization of debt issuance costs, recurring lease commissions, and other items.

Management believes that reporting AFFO in addition to FFO is a useful supplemental measure for the investment community to use when evaluating the operating performance of the Company on a comparative basis.

(as of March 31, 2023)

## **Reporting Definitions (continued)**

### **Rent Coverage Ratio**

For purposes of calculating our portfolio weighted-average EBITDARM coverage ratio ("Rent Coverage Ratio"), we excluded credit-rated tenants or their subsidiaries for which financial statements were either not available or not sufficiently detailed. These ratios are based on latest available information only. Most tenant financial statements are unaudited and we have not independently verified any tenant financial information (audited or unaudited) and, therefore, we cannot assure you that such information is accurate or complete. Certain other tenants (approximately 20% of our portfolio) are excluded from the calculation due to (i) lack of available financial information or (ii) small tenant size. Additionally, included within 20% of non-reporting tenants is Pipeline Healthcare, LLC, which filed for Chapter 11 bankruptcy protection in October of 2022. Additionally, our Rent Coverage Ratio adds back physician distributions and compensation. Management believes all adjustments are reasonable and necessary.

## **Other Disclosures**

### **Non-GAAP Financial Measures**

Management considers certain non-GAAP financial measures to be useful supplemental measures of the Company's operating performance. For the Company, non-GAAP measures consist of EBITDAre, Adjusted EBITDAre, FFO and AFFO. A non-GAAP financial measure is generally defined as one that purports to measure financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable measure determined in accordance with GAAP. The Company reports non-GAAP financial measures because these measures are observed by management to also be among the most predominant measures used by the REIT industry and by industry analysts to evaluate REITs. For these reasons, management deems it appropriate to disclose and discuss these non-GAAP financial measures.

The non-GAAP financial measures presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income, as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs. Management believes that in order to facilitate a clear understanding of the Company's historical consolidated operating results, these measures should be examined in conjunction with net income and cash flows from operations as presented elsewhere herein.

### **Additional Information**

The information in this document should be read in conjunction with the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other information filed with, or furnished to, the SEC. You can access the Company's reports and amendments to those reports filed or furnished to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act in the "Investor Relations" section on the Company's website ([www.globalmedicalreit.com](http://www.globalmedicalreit.com)) under "SEC Filings" as soon as reasonably practicable after they are filed with, or furnished to, the SEC. The information on or connected to the Company's website is not, and shall not be deemed to be, a part of, or incorporated into, this Earnings Supplemental. You also can review these SEC filings and other information by accessing the SEC's website at <http://www.sec.gov>.

Certain information contained in this package, including, but not limited to, information contained in our Top 10 tenant profiles is derived from publicly-available third-party sources. The Company has not independently verified this information and there can be no assurance that such information is accurate or complete.



**GLOBAL  
MEDICAL REIT**

[www.globalmedicalreit.com](http://www.globalmedicalreit.com)  
**NYSE: GMRE**



## **INVESTOR RELATIONS**

Stephen Swett  
[stephen.swett@icrinc.com](mailto:stephen.swett@icrinc.com)

203.682.8377

